Shoulder Joint Replacement — Clinical Guide (TSA, RSA & Hemiarthroplasty) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Shoulder joint replacement (shoulder arthroplasty) encompasses a family of surgical procedures that replace the diseased or damaged articular surfaces of the glenohumeral joint with prosthetic components. The procedure reliably abolishes pain, restores range of motion, and improves function in patients with end-stage glenohumeral arthritis, cuff-tear arthropathy, and complex proximal humerus fractures refractory to other treatments.

Three main prosthetic designs are in clinical use:

• Total Shoulder Arthroplasty (TSA): Replaces both the humeral head (ball) and the glenoid surface (socket) with prosthetic components. The anatomical ball-and-socket geometry is maintained. Requires an intact and functional rotator cuff for stable centred glenohumeral mechanics. TSA is the procedure of choice for primary glenohumeral osteoarthritis (OA), rheumatoid arthritis with preserved cuff, and post-traumatic arthritis.
• Reverse Shoulder Arthroplasty (RSA): Inverts the ball-and-socket geometry by placing a metallic hemisphere (glenosphere) on the glenoid and a concave polyethylene cup on the humeral stem. This constrained design lowers the centre of rotation, medialises the glenohumeral joint, and recruits the deltoid muscle as the primary motor for elevation — bypassing the absent or non-functional rotator cuff. RSA is the treatment of choice for cuff-tear arthropathy, massive irreparable rotator cuff tears with pseudoparalysis, and as the revision procedure for failed TSA with cuff failure. It is also used for complex proximal humerus fractures in elderly patients (age >70 years).
• Resurfacing Hemiarthroplasty: Only the humeral head is resurfaced with a low-profile metal cap, preserving the native glenoid. Indicated for focal humeral head avascular necrosis (AVN) with a healthy glenoid, early glenohumeral OA, and young active patients (<50 years) in whom glenoid replacement should be deferred.

The choice between TSA and RSA is fundamentally determined by the integrity of the rotator cuff. Patients with an intact cuff undergo TSA; those with irreparable cuff tears, pseudoparalysis, or cuff-tear arthropathy undergo RSA. This distinction is established pre-operatively by MRI, CT arthrogram, and clinical examination (elevation lag sign, external rotation lag sign, hornblower's sign).

NICE Technology Appraisal TA460 (2017) supports the use of reverse shoulder prostheses for cuff-tear arthropathy and failed shoulder arthroplasty as cost-effective interventions within the NHS.

Shoulder arthroplasty addresses a spectrum of end-stage glenohumeral pathology that has failed to respond to non-operative treatment or is beyond the scope of joint-preserving arthroscopic surgery:

• Primary glenohumeral osteoarthritis (OA): The most common indication for TSA. Characterised by posterior glenoid wear (B-type glenoid morphology — Walch classification), posterior subluxation of the humeral head, and loss of joint space. TSA achieves pain scores (VAS) of <2/10 in 85–90% of patients at 5 years.
• Rheumatoid arthritis: Symmetrical inflammatory arthritis causing glenohumeral erosion, periarticular osteopenia, and central glenoid erosion (E-type Walch). The rotator cuff is frequently compromised in long-standing disease, influencing the choice between TSA and RSA.
• Cuff-tear arthropathy (CTA): Secondary glenohumeral OA arising from chronic massive rotator cuff deficiency. The humeral head migrates superiorly, erodes the acromion and AC joint (acetabularisation), and the glenoid shows characteristic superior erosion (Seebauer Type IA–II). RSA is the standard of care.
• Massive irreparable rotator cuff tear with pseudoparalysis: Complete inability to actively elevate the arm above 90° in the context of an irreparable tear, even without established glenohumeral OA. RSA provides predictable restoration of elevation in >80% of patients.
• Post-traumatic arthritis: Arising from malunion, hardware complications, or avascular necrosis following proximal humerus fractures. Component choice is guided by rotator cuff status and glenoid bone stock.
• Avascular necrosis (AVN) of the humeral head: Stages III–IV Cruess AVN with articular collapse. Resurfacing or stemmed hemiarthroplasty preserves the glenoid in younger patients; TSA is preferred if glenoid cartilage is also damaged.
• Complex proximal humerus fractures (Neer 3- and 4-part): In patients aged >65–70 years or when articular segment viability is compromised, acute RSA (or hemiarthroplasty) provides more predictable outcomes than fixation. Large multicentre randomised trials (PROFHER) have demonstrated that non-operative management is equivalent to surgical fixation for most displaced proximal humerus fractures, reserving arthroplasty for specific fracture patterns with very poor reconstructive potential.
• Failed previous shoulder arthroplasty: Aseptic glenoid component loosening, periprosthetic fracture, instability, or rotator cuff failure after TSA are managed by revision to RSA.

Appropriate patient selection is the most important determinant of long-term arthroplasty success. Pre-operative workup includes clinical, radiological, and functional assessment:

Clinical Criteria

• Persistent pain unresponsive to conservative treatment: A minimum 6-month trial of analgesics, physiotherapy, and intra-articular corticosteroid injections (up to 3 injections) is recommended before arthroplasty referral, except in cases of acute fracture or rapidly destructive arthritis.
• Functional limitation: Inability to perform activities of daily living (dressing, hygiene, reaching) or significant impairment of occupational and recreational activities.
• Radiological confirmation: Standing anteroposterior (AP) and axillary lateral shoulder X-rays showing glenohumeral joint space loss, subchondral sclerosis or cysts, osteophytes, or glenoid erosion. CT of the glenoid is performed in all arthroplasty candidates to classify glenoid morphology (Walch/Bercik classification), measure version and inclination, and assess bone stock for component fixation.

Rotator Cuff Assessment (Critical for Implant Selection)

• MRI (or CT arthrogram) is performed in all patients to assess rotator cuff integrity, degree of fatty infiltration (Goutallier classification), and tendon retraction (Patte classification).
• Patients with Goutallier Grade ≥3 fatty infiltration of the supraspinatus or infraspinatus are unlikely to achieve balanced post-TSA mechanics and should be considered for RSA.
• Clinical lag signs (external rotation lag for infraspinatus, hornblower's for teres minor) confirm functional cuff deficiency.

Bone Stock Assessment

• Adequate glenoid bone stock is essential for secure component fixation. Walch B2/B3 glenoids (significant posterior wear with retroversion) may require asymmetric reaming, bone grafting, or augmented glenoid components to correct version.
• Severely medialized glenoids or eroded glenoids (E-type) may limit TSA feasibility and favour RSA.

General Medical Fitness

• Cardiovascular and respiratory optimisation before elective arthroplasty
• Diabetes optimisation (HbA1c <69 mmol/mol / 8.5% to reduce infection risk)
• Smoking cessation (at least 6 weeks pre-operatively) to improve wound healing and osseointegration
• BMI reduction if >40 kg/m² to reduce implant loading and infection risk
• Dental health: treat active dental infection before arthroplasty to reduce haematogenous periprosthetic joint infection risk

The choice of implant and surgical technique in shoulder arthroplasty reflects the underlying diagnosis, glenoid morphology, rotator cuff status, and patient age and activity level:

Total Shoulder Arthroplasty (TSA) — Implant Components

• Glenoid component: The standard glenoid implant is an all-polyethylene (UHMWPE) component fixed with polymethylmethacrylate (PMMA) bone cement. Two anchor peg designs are used: keeled (a central fin inserted into a slot cut in the glenoid vault) and pegged (multiple cylindrical pegs providing superior primary stability — the current consensus preference). Meta-analyses show lower loosening rates with pegged cemented designs. Cementless metal-backed glenoid components (ingrowth via porous titanium backing) have historically shown higher failure rates due to polyethylene wear and backside fretting and are now largely abandoned outside specific registries.
• Humeral component: The humeral stem is available in cemented and press-fit (cementless) configurations. Modern short-stem and stemless humeral implants (Simpliciti, TESS) are increasingly used in younger patients to preserve proximal humeral bone stock and simplify future revision. Registry data (CORR, NJR) show equivalent 5–10 year outcomes for cemented and cementless humeral stems in primary TSA. Cementing is preferred in osteoporotic bone (Singh Grade ≤3).
• Humeral head sizing: Anatomical reconstruction of the native head diameter, height, and retroversion (typically 20–35°) is critical to avoid posterior instability and eccentric glenoid loading (the "rocking horse" phenomenon that leads to glenoid loosening).

Reverse Shoulder Arthroplasty (RSA) — Design Principles

• The Grammont design (1985, Delta III) established the modern RSA principle: the glenosphere is fixed to the glenoid with a central screw, and the polyethylene cup articulates on the humeral stem. Lateralised glenosphere designs (increasing glenosphere offset from 0 to 10–15 mm) have reduced notching (scapular notching — impingement of the polyethylene cup on the inferior scapular neck, classified Sirveaux Grades I–IV) and improved external rotation compared to original Grammont designs.
• RSA relies entirely on the deltoid muscle for active elevation. The distalised, medialised centre of rotation increases the deltoid moment arm, improving its mechanical advantage. However, post-operative external rotation is poor without a functioning teres minor — "teres minor-deficient" RSA patients may require latissimus dorsi transfer for active external rotation.
• Glenoid baseplate fixation uses a central screw (locking, divergent iliac screw design) ± supplementary peripheral screws. Inferior tilt of the baseplate (10–15°) reduces notching and improves inferior tension. Screw purchase in the scapular body (superior/inferior screws) is more important for fixation strength than the central peg alone.

Surgical Approach

The standard approach is the deltopectoral approach — developed through the internervous plane between the deltoid (axillary nerve) and pectoralis major (medial/lateral pectoral nerves). The subscapularis is reflected (tenotomy or lesser tuberosity osteotomy) and repaired at closure. The superior approach (deltoid split) is used by some surgeons for RSA and fracture cases. Subscapularis repair integrity is a critical determinant of post-operative anterior stability in TSA.

Shoulder arthroplasty achieves reliable, durable improvements in pain and function supported by extensive registry and clinical trial data:

Pain Relief

The most consistent outcome of shoulder arthroplasty is dramatic pain reduction. Mean Visual Analogue Scale (VAS) pain scores improve from 7–8/10 pre-operatively to 1–2/10 at 12 months, with 85–92% of patients reporting significant or complete pain relief. The degree of pain relief is comparable to total hip and knee arthroplasty and is maintained at long-term follow-up.

Oxford Shoulder Score (OSS)

The OSS (scored 0–48, higher = better outcome) is the validated patient-reported outcome measure used in the NHS and internationally. Mean pre-operative OSS for glenohumeral OA is 20–24; post-operative TSA achieves a mean OSS of 41–43 at 12 months, representing a mean improvement of 20–23 points — well above the minimum clinically important difference (MCID) of 10.4 points.

Functional Restoration

• TSA: Mean active forward flexion improves from 90–100° pre-operatively to 140–155° at 12 months. External rotation improves from 20° to 45–55°.
• RSA: Active forward flexion improves from 40–60° (in pseudoparalysis) to 110–130°. External rotation improvement is limited to 15–25° unless a teres minor transfer is performed.

Registry and Long-Term Survival Data

• Clinical Orthopaedic Research Registry (CORR) and National Joint Registry (NJR, UK): Report revision rates of 5–10% at 10 years for primary TSA and RSA. Glenoid component loosening is the most common failure mode for TSA (accounting for 30–40% of revisions); instability is the most common failure mode for RSA.
• Implant survival: 90% at 10 years; 80–85% at 15 years for primary TSA with cemented pegged glenoid components (NJR data, 2023 Annual Report).
• RSA outcomes: Post-operative active elevation >90° in >85% of RSA patients with pseudoparalysis; patient satisfaction rates of 82–88% at 5 years.

Quality of Life

SF-36 and EQ-5D quality of life assessments demonstrate significant improvements across physical function, pain, and general health domains following shoulder arthroplasty, with gains maintained at 5–10 years. Shoulder arthroplasty compares favourably in cost-utility analyses with other well-established orthopaedic procedures.

Shoulder arthroplasty is a major orthopaedic procedure with a recognised complication profile. Understanding these risks is essential for informed consent and shared decision-making:

Intraoperative Complications

• Humeral fracture: Intraoperative proximal humerus fractures occur in 1–3% of cases, particularly in osteoporotic bone during stem insertion. Greater tuberosity fractures may compromise subscapularis or rotator cuff repair.
• Glenoid vault perforation: Over-reaming or misaligned drilling can perforate the glenoid vault, complicating component fixation. CT-guided planning and patient-specific instrumentation (PSI) reduce this risk.
• Neurovascular injury: Axillary nerve injury (the most vulnerable structure, lying 5–6 cm distal to the acromion) is rare but serious (<0.5%). Brachial plexus stretch injury can occur with excessive retraction.

Early Post-Operative Complications (Within 90 Days)

• Periprosthetic joint infection (PJI): Incidence 0.7–1.5%. Propionibacterium acnes (Cutibacterium acnes) is the most common organism in shoulder PJI — a slow-growing organism residing in pilosebaceous units. It may cause indolent late infection and is frequently missed on standard cultures (requires 14+ days incubation). Staphylococcal infection, while less common, is more clinically aggressive and carries a higher revision burden.
• Subscapularis failure: Failure of subscapularis repair or tenotomy healing leads to anterior instability and external rotation contracture. Incidence 1–5% with standard tenotomy; lesser tuberosity osteotomy may improve healing rates.
• Wound complications: Haematoma, serous discharge, superficial wound dehiscence — collectively occurring in 2–4% of cases.

Late Complications

• Glenoid component loosening (TSA): The "rocking horse" mechanism — eccentric loading from residual rotator cuff imbalance — causes progressive polyethylene glenoid loosening, the leading cause of TSA revision at 10–15 years. Radiolucent lines around the glenoid component on serial X-rays are an early radiological warning sign.
• Scapular notching (RSA): Impingement of the polyethylene cup against the inferior scapular neck causes osteolysis and notching (Sirveaux classification). Lateralised glenosphere designs have reduced incidence from ~30% to <10% in modern prostheses.
• Instability/dislocation (RSA): Anterior, posterior, or inferior dislocation occurs in 2–4% of RSA cases. Caused by component malposition, inadequate soft tissue tension, or subscapularis incompetence.
• Periprosthetic fracture: Humerus fractures around a stemmed prosthesis require complex revision surgery.
• Acromial stress fracture: Unique to RSA — tensioning of the deltoid increases acromial stress. Acromion and spine of scapula stress fractures occur in 2–4% of RSA cases and often require non-operative management with prolonged immobilisation.

Rehabilitation after shoulder arthroplasty follows a phased protocol guided by the procedure performed, subscapularis repair status, and patient age and fitness:

Immediate Post-Operative Period (Days 0–3)

• Single-use cryotherapy devices and scheduled oral analgesia (paracetamol, NSAIDs, short-course opioids) manage initial post-operative pain.
• The arm is rested in a polysling at the side, with the forearm supported. Early pendulum exercises begin on post-operative Day 1 under nursing supervision.
• Hospital discharge is typically at 1–3 nights for TSA/RSA in standard cases.
• Deep vein thrombosis (DVT) prophylaxis with low molecular weight heparin (LMWH) is given for 14 days in high-risk patients; chemical prophylaxis is not universally recommended for shoulder arthroplasty (lower DVT risk than lower limb arthroplasty).

Phase 1: Passive Phase (Weeks 1–6)

• Sling worn for 4–6 weeks (longer in cases with subscapularis repair or RSA requiring deltoid tension protection).
• Physiotherapy initiated at Week 1–2 focusing on passive range of motion: shoulder flexion, external rotation within prescribed limits (usually <30° post-TSA to protect subscapularis repair).
• Elbow, wrist, and hand exercises performed hourly to prevent contracture.
• Wound review at 10–14 days; suture removal if non-absorbable sutures used.

Phase 2: Active-Assisted Phase (Weeks 6–12)

• Sling discontinued. Active-assisted exercises with a pulley system and contralateral arm assistance.
• External rotation to 45° and forward flexion to 120° targeted by week 10.
• Scapular stabilisation exercises commence (lower trapezius, serratus anterior).

Phase 3: Strengthening Phase (Weeks 12–24)

• Progressive resistance exercises with light resistance bands, targeting the deltoid (RSA) and rotator cuff (TSA).
• Functional activities: reaching overhead, driving (typically safe at 8–10 weeks if non-dominant, 12–16 weeks if dominant arm).
• Return to golf at 3–4 months; recreational sport at 4–6 months.

Long-Term Follow-Up

Annual clinical and radiological review is recommended indefinitely for all shoulder arthroplasty patients to detect early glenoid loosening, component wear, and implant migration on serial X-rays. The Oxford Shoulder Score is routinely collected at 6 weeks, 6 months, 12 months, and annually thereafter as part of NHS Patient Reported Outcome Measures (PROMS) data collection.

Shoulder arthroplasty is a major elective procedure with significant cost variation across healthcare systems, prosthesis types, and geographic regions:

Global Cost Benchmarks (Private / Self-Pay, 2025 Data)

• United Kingdom (private): GBP 12,000–20,000 for primary TSA; GBP 14,000–24,000 for RSA. NHS patients on appropriate referral pathways receive shoulder arthroplasty at no direct cost; typical waiting times are 12–18 months for elective cases.
• United States: USD 25,000–45,000 (total facility and professional fees). Medicare reimbursement rates are significantly lower; actual out-of-pocket costs vary considerably with insurance plan design and deductible.
• India (JCI-accredited hospitals): USD 5,000–9,000 for primary TSA; USD 6,000–11,000 for RSA. India offers equivalent implant brands (Depuy Synthes, Zimmer Biomet, Stryker) at 70–80% lower cost than Western markets, with comparable surgical outcomes at leading orthopaedic centres in Delhi, Mumbai, and Chennai.
• Thailand / Singapore: USD 10,000–18,000 (TSA/RSA) at internationally accredited hospitals.
• Germany / Switzerland: EUR 18,000–28,000 for primary arthroplasty at private hospitals.

Key Cost Drivers

• Prosthesis type and brand: Stemless implants (e.g., Simpliciti TSA by Wright Medical) cost USD 3,000–5,000 per implant unit. RSA systems (Tornier Aequalis, Depuy Delta Xtend, Zimmer Biomet Comprehensive) cost USD 4,000–8,000 per system. Patient-specific instrumentation adds USD 500–1,500.
• Revision arthroplasty: Costs 40–60% more than primary procedures due to increased operative complexity, longer theatre time, and need for augmented glenoid components or bone grafting.
• Rehabilitation: Post-operative physiotherapy (6–12 months) adds USD 1,500–5,000 in systems without universal coverage.
• Surgeon experience: Fellowship-trained upper limb arthroplasty surgeons have lower complication and revision rates, reducing the long-term cost of care despite higher initial fees.

Cost-effectiveness analyses consistently demonstrate that shoulder arthroplasty achieves a cost per QALY (quality-adjusted life year) well within accepted thresholds (<GBP 20,000 per QALY in UK; <USD 50,000 in USA), supporting its provision as a publicly funded procedure.

Before proceeding to shoulder arthroplasty, the following alternatives should be considered and documented as having been tried or considered in the shared decision-making process:

Physiotherapy and Exercise

Supervised exercise therapy focusing on scapular stabilisation, rotator cuff strengthening, and proprioceptive retraining is the first-line treatment for glenohumeral OA with moderate symptoms. While physiotherapy cannot restore lost articular cartilage, it reduces pain, improves muscle activation patterns, and may delay the need for arthroplasty by 2–5 years in patients with mild-to-moderate disease.

Intra-articular Corticosteroid Injections

Ultrasound-guided glenohumeral corticosteroid injection (triamcinolone 40 mg or methylprednisolone 80 mg) provides 8–16 weeks of meaningful pain relief in 60–70% of patients with glenohumeral OA. Repeated injections are safe for up to 3 administrations per year, though more frequent injection may impair cartilage matrix integrity. NICE guidelines advise a minimum interval of 3 months between injections.

Hyaluronic Acid (Viscosupplementation)

Intra-articular hyaluronic acid injection is used by some centres for glenohumeral OA. Evidence is moderate — a 2021 systematic review showed modest short-term pain relief superior to placebo but inferior to corticosteroid at 4–6 weeks, with possibly longer duration of effect (12–26 weeks).

Arthroscopic Joint Debridement

Arthroscopic washout, loose body removal, and chondral debridement provide temporary symptomatic relief in early-to-moderate glenohumeral OA with mechanical symptoms. This is a joint-preserving option that delays but does not prevent eventual arthroplasty.

Biological Therapies

DMARDs (methotrexate, biological agents — anti-TNF, IL-6 inhibitors) can substantially slow glenohumeral joint destruction in rheumatoid arthritis and may obviate or significantly delay the need for arthroplasty when initiated early in the disease course. Rheumatology co-management is essential for inflammatory arthropathy.

Resurfacing Hemiarthroplasty

In patients under 50 years with preserved glenoid cartilage and avascular necrosis of the humeral head, resurfacing hemiarthroplasty (e.g., Copeland or GLOBAL CAP) is a bone-conserving alternative to stemmed TSA that preserves future revision options.